Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Meningococcal conjugate vaccines.

Shanta M Zimmer1, David S Stephens

  • 1Department of Medicine, Emory University School of Medicine, Emory University Hospital, Atlanta, GA 30322, USA.

Expert Opinion on Pharmacotherapy
|April 23, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genomic Typing of Meningococcal Carriage Isolates in an Urban Sexual Health Clinic.

Pathogens (Basel, Switzerland)·2026
Same author

Reviving the Sciences: a Post-clerkship Approach to Required Basic Science Education.

Medical science educator·2026
Same author

Perspective on the pathogenic Neisseria: milestones, challenges, and future directions.

NPJ vaccines·2026
Same author

Emerging and Pandemic Pathogens: Lessons Learned From a Clinical Research Network.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2025
Same author

Future Goals and Long-term Vision of the Infectious Diseases Clinical Research Consortium/Vaccine and Treatment Evaluation Unit Network.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2025
Same author

Baptism in a Pandemic: Infectious Diseases Clinical Research Consortium Network Design for Readiness and Response.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2025

Meningococcal conjugate vaccines offer improved protection against bacterial meningitis compared to older vaccines. New conjugate vaccines show high efficacy in children and adolescents, with more targeting other serogroups under development.

Area of Science:

  • Microbiology
  • Immunology
  • Vaccinology

Background:

  • Neisseria meningitidis causes bacterial meningitis and sepsis globally, with over 500,000 cases and 135,000 deaths annually.
  • Meningococcal disease survivors often suffer severe neurological sequelae, impacting quality of life.
  • Existing polysaccharide vaccines have limitations in immunogenicity, especially in children, and do not provide long-lasting immunity.

Purpose of the Study:

  • To review the development and efficacy of meningococcal conjugate vaccines.
  • To highlight the potential impact of conjugate vaccines on preventing meningococcal disease worldwide.
  • To discuss the ongoing challenges in developing a serogroup B meningococcal vaccine.

Main Methods:

  • Review of existing literature on meningococcal conjugate vaccines.

Related Experiment Videos

  • Analysis of clinical trial data for newly released conjugate vaccines.
  • Discussion of vaccine technology advancements and their application to meningococcal disease.

    • Main Results:

    • Newly developed meningococcal conjugate vaccines against serogroup C demonstrate high efficacy and minimal side effects in young populations.
    • Conjugate vaccine technology has proven successful for other bacterial meningitis pathogens.
    • Development of conjugate vaccines for serogroups A, Y, and W-135 is ongoing and shows promise.

    Conclusions:

    • Meningococcal conjugate vaccines represent a significant advancement over polysaccharide vaccines, offering improved immunogenicity and durability.
    • These vaccines have the potential to substantially reduce the global burden of meningococcal disease, both sporadic and epidemic.
    • Further research is needed to address the challenge of developing an effective serogroup B meningococcal vaccine.